Cellular senescence is a complex and multistep biological process which cells can undergo in response to different stresses. Referring to a highly stable cell cycle arrest, cellular senescence can influence a multitude of biological processes—both physiologically and pathologically. While phenotypically diverse, characteristics of senescence include the expression of the senescence-associated secretory phenotype, cell cycle arrest factors, senescence-associated β-galactosidase, morphogenesis, and chromatin remodelling. Persistent senescence is associated with pathologies such as aging, while transient senescence is associated with beneficial programmes, such as limb patterning. With these implications, senescence-based translational studies, namely senotherapy and pro-senescence therapy, are well underway to find the cure to complicated diseases such as cancer and atherosclerosis. Being a subject of major interest only in the recent decades, much remains to be studied, such as regarding the identification of unique biomarkers of senescent cells. This review attempts to provide a comprehensive understanding.
細(xì)胞衰老是一個復(fù)雜的、多步驟的生物過程,細(xì)胞可以對不同的壓力做出反應(yīng)。提到高度穩(wěn)定的細(xì)胞周期停滯,細(xì)胞衰老會影響多種生理過程和病理過程。雖然表型多樣,但衰老的特征包括衰老相關(guān)分泌表型的表達(dá)、細(xì)胞周期停滯因子、衰老相關(guān)的 β-半乳糖苷酶、形態(tài)發(fā)生和染色質(zhì)重塑。持續(xù)衰老與衰老等病理相關(guān),而短暫衰老與有益程序相關(guān),如肢體模式。有了這些影響,基于衰老的轉(zhuǎn)化研究,即衰老療法和促衰老療法,正在尋找治愈癌癥和動脈粥樣硬化等復(fù)雜疾病的方法。作為僅在最近幾十年才受到關(guān)注的主要課題,仍有許多需要研究,例如關(guān)于衰老細(xì)胞獨特生物標(biāo)志物的鑒定。本綜述試圖全面了解有關(guān)衰老的各種文獻,并討論我們迄今為止對衰老的了解。
Senotherapy is concerned with the development of therapeutic strategies to slowthe ageing process and alleviate its associated diseases by preventing, eliminating, or reversing senescence in cells [145]. Although much of this study is still exploratory, and no drugs have been approved for clinical use, many different strategies have been identified.Central to all is the use of senolytics. Senolytic therapy is one of the more, if not the most, rapidly developing strategy for senotherapy. Senolytic agents are a class of small molecules that have been found to be able to selectively induce the apoptosis of senescent cells by interfering with the SCAPs. Most senolytic drugs that have been identified so far are repurposed anti-cancer drugs, such as the likes of dasatinib and quercetin (used in combination)—the first few senolytics to be discovered. The combination of these two drugs has been widely demonstrated to induce the apoptosis of senescent cells in cultured human tissues and in mouse models [146–148]. In one of the mouse models,the bi-weekly administration of dasatinib and quercetin on aged mice showed a 36% higher median lifespan, while the mortality hazard was reduced to 64.9% [145]. This potential of the senolytic drugs has also been replicated in clinical trials—in the first-of-itskind Phase 1 clinical trial, the administration of dasatinib and quercetin on patients withidiopathic pulmonary fibrosis (IPF; a lung disease in which scarring of the lungs reduces their function) showed a significant improvement in physical functions (such as walking endurance) in the participants [149]. The following subsections briefly discusses some potential senolytics and some recent findings. The information is summarised in Table.
衰老細(xì)胞清除治療關(guān)注減緩治療策略的發(fā)展通過預(yù)防,消除或減輕其相關(guān)疾病逆轉(zhuǎn)細(xì)胞衰老。雖然這項研究的大部分仍然是探索性的,沒有藥物已被批準(zhǔn)用于臨床,已經(jīng)確定了許多不同的策略。所有人的核心是使用senolytics。溶解療法是其中之一,如果不是大多數(shù),快速發(fā)展的senotherapy戰(zhàn)略。溶解劑是一類小的已經(jīng)發(fā)現(xiàn)能夠選擇性誘導(dǎo)衰老細(xì)胞凋亡的分子細(xì)胞干擾SCAP。大多數(shù)已經(jīng)確定的溶解性藥物far是重新使用的抗癌藥物,如達(dá)沙替尼和槲皮素(使用結(jié)合起來)-首先發(fā)現(xiàn)的幾種衰老細(xì)胞清除治療。這些組合兩種藥物已被廣泛證明可誘導(dǎo)衰老細(xì)胞凋亡培養(yǎng)的人體組織和小鼠模型[146-148]。在其中一個鼠標(biāo)模型中,達(dá)沙替尼和槲皮素對老齡小鼠的雙周給藥率為36%中位壽命更長,而死亡危險降低至64.9%。這個衰老細(xì)胞清除治療藥物的潛力也在臨床試驗中首次被復(fù)制1期臨床試驗,達(dá)沙替尼和槲皮素治療患者特發(fā)性肺纖維化(IPF;肺部瘢痕減少的肺部疾病他們的功能)顯示了顯著改善身體功能。
關(guān)鍵詞: senescence; cancer; aging; senotherapy 衰老;癌癥;老化; 聲療
來源:MDPI https://www.mdpi.com/2227-9059/9/12/1769#cite
上一篇: 血清瓶可用于青霉素-鏈霉素溶液的儲存
下一篇: PETG材料在血清瓶中的應(yīng)用